Company news

Lumosa Therapeutics Co Ltd news in 2022

Lumosa Therapeutics Co Ltd's news releases, calls and decks from 2022, newest first.

View company

Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic

August 9, 2022

Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company

August 9, 2022

Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards

August 9, 2022

Board of Directors approved the consolidated financial report for the second quarter of 2022

August 9, 2022

Board Approved the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic

May 31, 2022

Lumosa Therapeutics: Shareholders' Meeting approved to release the company's directors from non-competition restrictions

May 24, 2022

Lumosa Therapeutics: Important resolutions of LUMOSA's 2022 Annual Shareholders' Meeting

May 24, 2022

Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders

April 22, 2022

LUMOSA Therapeutics announces TFDA’s clearance of Phase 2 IND application for multiple-dose of LT3001 in patients with acute ischemic stroke.

March 24, 2022

Board of Directors approved the convening of the 2022 Annual shareholders' Meeting

March 4, 2022

Board of Directors approved to issue common shares via private placement.

March 4, 2022

Board of Directors approved the 2021 consolidated financial report

March 4, 2022

Lumosa Therapeutics Receives the Results of LT1001 Phase 3 Trial Conducted by Chinese Partner, Jemincare

February 25, 2022

Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke.

February 9, 2022

Lumosa Therapeutics Announces the Termination of “Comparative BA Study” for Naldebain, a New Long-Acting Analgesic Injection, in the US Due to Additional USFDA Requirements

January 26, 2022